CohBar (CWBR) 10-K 30 Mar 21 2020 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Mar. 25, 2021	Jun. 30, 2020
Document Information Line Items
Entity Registrant Name	CohBar, Inc.
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		61,788,325
Entity Public Float			$ 50,525,285
Amendment Flag	false
Entity Central Index Key	0001522602
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity File Number	001-38326
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 2,894,575	$ 12,563,853
Investments	18,120,266
Prepaid expenses and other current assets	413,692	361,311
Total current assets	21,428,533	12,925,164
Property and equipment, net	394,004	523,677
Intangible assets, net	18,075	19,154
Other assets	67,403	64,242
Total assets	21,908,015	13,532,237
Current liabilities:
Accounts payable	727,599	444,776
Accrued liabilities	1,141,741	916,692
Accrued payroll and other compensation	853,335	677,755
Note payable, net of debt discount and offering costs of $15,656 and $0 as of December 31, 2020 and 2019, respectively	349,344
Total current liabilities	3,072,019	2,039,223
Notes payable, net of debt discount and offering costs of $26,159 and $546,312 as of December 31, 2020 and 2019, respectively	348,841	3,356,188
Total liabilities	3,420,860	5,395,411
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value, Authorized 5,000,000 shares; No shares issued and outstanding as of December 31, 2020 and December 31, 2019, respectively
Common stock, $0.001 par value, Authorized 180,000,000 shares; Issued and outstanding 61,117,524 shares as of December 31, 2020 and 43,069,418 as of December 31, 2019	61,118	43,069
Additional paid-in capital	87,684,323	61,087,082
Accumulated deficit	(69,258,286)	(52,993,325)
Total stockholders’ equity	18,487,155	8,136,826
Total liabilities and stockholders’ equity	$ 21,908,015	$ 13,532,237

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Net of debt discount and offering costs (in Dollars)	$ 15,656	$ 0
Debt discount of note payable and offering costs, current (in Dollars)	$ 26,159	$ 546,312
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued
Preferred stock, outstanding
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, authorized	180,000,000	180,000,000
Common stock, issued	61,117,524	43,069,418
Common stock, outstanding	61,117,524	43,069,418

Condensed Statements of Operati

Condensed Statements of Operations (unaudited) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenues
Operating expenses:
Research and development	6,937,610	6,631,928
General and administrative	6,261,905	5,951,106
Total operating expenses	13,199,515	12,583,034
Operating loss	(13,199,515)	(12,583,034)
Other income (expense):
Interest income	41,149	290,313
Interest expense	(311,410)	(312,200)
Equity modification expense	(2,290,688)
Amortization of debt discount and offering costs	(504,497)	(439,851)
Total other expense	(3,065,446)	(461,738)
Net loss	$ (16,264,961)	$ (13,044,772)
Basic and diluted net loss per share (in Dollars per share)	$ (0.33)	$ (0.30)
Weighted average common shares outstanding - basic and diluted (in Shares)	48,814,353	42,816,616

Statements of Changes in Stockh

Statements of Changes in Stockholders’ Equity - USD ($)	Common Stock	APIC	Accumulated Deficit	Total
Balance at Dec. 31, 2018	$ 42,578	$ 57,868,593	$ (39,948,553)	$ 17,962,618
Balance (in Shares) at Dec. 31, 2018	42,578,208
Stock based compensation		2,609,370		2,609,370
Exercise of employee stock options	$ 441	551,669		552,110
Exercise of employee stock options (in Shares)	441,210
Exercise of warrants	$ 50	57,450		57,500
Exercise of warrants (in Shares)	50,000
Net loss			(13,044,772)	(13,044,772)
Balance at Dec. 31, 2019	$ 43,069	61,087,082	(52,993,325)	8,136,826
Balance (in Shares) at Dec. 31, 2019	43,069,418
Stock based compensation		2,216,316		2,216,316
Equity modification expense		2,290,688		2,290,688
Exercise of employee stock options	$ 224	252,161		252,385
Exercise of employee stock options (in Shares)	223,924
Exercise of warrants	$ 20	44,980		45,000
Exercise of warrants (in Shares)	20,000
Sale of common stock in ATM, net	$ 2,350	4,306,002		4,308,352
Sale of common stock in ATM, net (in Shares)	2,350,067
Sale of common stock in CMPO, net	$ 12,300	13,643,231		13,655,531
Sale of common stock in CMPO, net (in Shares)	12,300,000
Issuance of equity to convert debt	$ 3,155	3,843,863		3,847,018
Issuance of equity to convert debt (in Shares)	3,154,115
Net loss			(16,264,961)	(16,264,961)
Balance at Dec. 31, 2020	$ 61,118	$ 87,684,323	$ (69,258,286)	$ 18,487,155
Balance (in Shares) at Dec. 31, 2020	61,117,524

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (16,264,961)	$ (13,044,772)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	156,664	147,687
Stock-based compensation	2,216,316	2,609,370
Equity modification expense	2,290,688
Amortization of debt discount	463,781	420,341
Amortization of debt issuance costs	40,716	19,510
Discount on investments	2,734	(34,574)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(52,381)	(100,681)
Accounts payable	282,823	(697,959)
Accrued liabilities	909,567	564,879
Accrued payroll and other compensation	175,580	10,094
Net cash used in operating activities	(9,778,473)	(10,106,105)
Cash flows from investing activities:
Purchases of property and equipment	(25,912)	(149,545)
Payment for security deposit	(3,161)	(7,449)
Purchases of investments	(25,417,000)	(40,348,000)
Proceeds from redemptions of investments	7,294,000	56,843,000
Net cash (used in) provided by investing activities	(18,152,073)	16,338,006
Cash flows from financing activities:
Proceeds from public offering, net	13,655,531
Proceeds from the At-the-Market Offering, net	4,308,352
Proceeds from exercise of warrants	45,000	57,500
Proceeds from exercise of employee stock options	252,385	552,110
Net cash provided by financing activities	18,261,268	609,610
Net (decrease) increase in cash and cash equivalents	(9,669,278)	6,841,511
Cash and cash equivalents at beginning of period	12,563,853	5,722,342
Cash and cash equivalents at end of period	2,894,575	12,563,853
Non-cash financing activities:
Conversion of Promissory Notes to Common Stock	3,847,018
Supplemental disclosure of cash flow information:
Cash paid for income taxes	$ 1,300	$ 1,300

Business Organization and Natur

Business Organization and Nature of Operations	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
BUSINESS ORGANIZATION AND NATURE OF OPERATIONS	Note 1 - Business Organization and Nature of Operations CohBar, Inc. (“CohBar,” “its” or the “Company”) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics (“MBTs”), an emerging class of drugs for the treatment of chronic and age-related diseases including nonalcoholic steatohepatitis (“NASH”), obesity, cancer, fibrotic diseases such as idiopathic pulmonary fibrosis, acute respiratory distress syndrome (‘ARDS’) including COVID-19 associated ARDS, type 2 diabetes mellitus and cardiovascular and neurodegenerative diseases. The Company’s primary activities include the research and development of its MBT pipeline, securing intellectual property protection for its discoveries and assets, managing collaborations and clinical trials with contract research organizations (“CROs”) and raising capital to fund the Company’s operations. To date, the Company has not generated any revenues from operations and does not expect to generate any revenues in the near future. The Company has financed its operations primarily with proceeds from sales of its equity securities, private placements, the exercise of outstanding warrants and stock options and the issuance of debt instruments. The Company is monitoring the COVID-19 pandemic, which continues to rapidly evolve, and has taken steps to mitigate the potential impacts on its business. The extent to which the pandemic may impact the Company’s business, preclinical studies and its clinical trial will depend on future developments, which are highly uncertain and cannot be predicted with confidence. The Company has modified its business practices by restricting nonessential travel, implementing a partial work from home policy for its employees and instituting new safety protocols for its lab to enable essential on-site work to continue. The Company expects to continue to take actions that are in the best interests of its employees and business partners. Due to the uncertainty surrounding the pandemic, the Company’s visibility into the duration of these actions is limited.

Liquidity and Management's Plan

Liquidity and Management's Plans	12 Months Ended
	Dec. 31, 2020
Managements Liquidity Plans Disclosure [Abstract]
LIQUIDITY AND MANAGEMENT'S PLANS	Note 2 – Liquidity and Management’s Plans As of December 31, 2020, the Company had a cash and cash equivalents balance of $2,894,575 and working capital and stockholders’ equity of $18,356,514 and $18,487,155, respectively. During the year ended December 31, 2020, the Company incurred a net loss of $16,264,961. As reflected in the financial statements, the Company had an accumulated deficit as of December 31, 2020 and 2019, as well as recurring losses and negative cash flows from operating activities from inception. These factors raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the issuance of these financial statements. However, based on current budget assumptions, projected cash burn, the cash and investments on hand as of December 31, 2020 and funding of approximately $1 million received from equity exercises subsequent to December 31, 2020, the Company believes that it has sufficient capital to meet its operating expenses and obligations for the next twelve months from the date of this filing. However, if unanticipated difficulties or circumstances arise, the Company may require additional capital sooner to support its operations. If the Company is unable to raise additional capital whenever necessary, it may be forced to decelerate or curtail its research and development activities and/or other operations until such time as additional capital becomes available. Such limitation of the Company’s activities would allow it to slow its rate of spending and extend its use of cash until additional capital is raised. There can be no assurance that such a plan would be successful. There is no assurance that additional financing will be available when needed or that the Company will be able to obtain such financing on reasonable terms.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Note 3 - Summary of Significant Accounting Policies Basis of Presentation All amounts are presented in U.S. Dollars. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at dates of the financial statements and the reported amounts of revenue and expenses during the periods. Actual results could differ from these estimates. The Company’s significant estimates and assumptions include the fair value of financial instruments, stock-based compensation and the valuation allowance relating to the Company’s deferred tax assets. Concentrations of Credit Risk The Company maintains deposits in a financial institution which is insured by the Federal Deposit Insurance Corporation (“FDIC”). At various times, the Company has deposits in this financial institution in excess of the amount insured by the FDIC. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk. Investments Investments as of December 2020 and 2019 consist of U.S. Treasury Bills, which are classified as held-to-maturity, and Certificates of Deposit totaling $18,120,266 and $0, respectively. The Company determines the appropriate balance sheet classification of its investments at the time of purchase and evaluates the classification at each balance sheet date. All of the Company’s U.S. Treasury Bills mature within the subsequent twelve months from the date of purchase. Unrealized gains and losses were de minimus Capitalization of Patent Costs The Company capitalizes the costs of its patents which consists of legal and filing fees related to the prosecution of patent filings. The patents will be amortized using the straight-line method over the estimated remaining lives of the patents which is 20 years from the initial filing of the patent. Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of December 31, 2020, the Company did not have any cash equivalents. As of December 31, 2019, the Company invested $9,505,777 in Treasury Bills that are considered cash equivalents due to their maturity date being less than three months from the date of purchase. Property and Equipment, net Property and equipment are stated at cost less accumulated depreciation. Depreciation of computer and lab equipment is computed by use of the straight-line method based on the estimated useful lives of the assets, which range from three to five years. Expenditures for maintenance and repairs that do not improve or extend the expected lives of the assets are expensed to operations, while expenditures for major upgrades to existing items are capitalized. Upon retirement or other disposition of these assets, the costs and accumulated depreciation are removed from the accounts and resulting gains or losses are reflected in the results of operations. Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company utilizes three levels of inputs that may be used to measure fair value: Level 1 - quoted prices in active markets for identical assets or liabilities Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions) The carrying amounts of cash, investments and accounts payable approximate fair value due to the short-term nature of these instruments. The amount of debt included in the accompanying balance sheets approximates its fair value because the interest rate of the notes approximates the current market interest rate. Common Stock Purchase Warrants The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provides the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company’s own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control), or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets, liabilities and equity is required. The Company’s free-standing derivatives consist of warrants to purchase common stock that were issued in connection with its notes payable and private offering. The Company evaluated these warrants to assess their proper classification using the applicable criteria enumerated under U.S. GAAP and determined that the common stock purchase warrants meet the criteria for equity classification in the accompanying balance sheets as of December 31, 2020 and 2019. Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The benefit of tax positions taken or expected to be taken in income tax returns are recognized in the financial statements if such positions are more likely than not of being sustained. Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s financial statements as of December 31, 2020 and 2019. The Company does not expect any significant changes in the unrecognized tax benefits within twelve months of the reporting date. The Company classifies interest expense and any related penalties related to income tax uncertainties as a component of income tax expense. No interest or penalties have been recognized during the years ended December 31, 2020 and 2019. Research and Development Expenses The Company expenses all research and development expenses as incurred. These costs include payroll, employee benefits, supplies, contracted for lab services, depreciation and other personnel-related costs associated with product development. Share-Based Payment The Company accounts for share-based payments using the fair value method. For employees and directors, the fair value of the award is measured, as discussed below, on the grant date. For non-employees, fair value is generally valued based on the fair value of the services provided or the fair value of the equity instruments on the measurement date, whichever is more readily determinable. The Company has granted stock options at exercise prices equal to the closing price of the Company’s common stock as reported by Nasdaq, with input from management on the date of grant. Upon exercise of an option or warrant, the Company issues new shares of common stock out of its authorized shares. The weighted-average fair value of options and warrants has been estimated on the grant date or measurement date using the Black-Scholes pricing model. The fair value of each instrument is estimated on the grant date or measurement date utilizing certain assumptions for a risk-free interest rate, volatility and expected remaining lives of the awards. The risk-free interest rate used is the United States Treasury rate for the day of the grant having a term equal to the life of the equity instrument. Beginning with the first quarter of the year ending 2019, the fair value of stock-based payment awards issued was estimated using a volatility derived from the Company’s share price. Prior to the first quarter of the year ending 2019, the Company had a limited history of being publicly traded and estimated the fair value of stock-based payment awards using a volatility derived from an index of comparable entities. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company’s stock-based compensation expense could be materially different in the future. The weighted-average Black-Scholes assumptions are as follows: For the Years Ended 2020 2019 Expected life 6 years 6 years Risk free interest rate 0.85 % 2.18 % Expected volatility 97 % 77 % Expected dividend yield 0 % 0 % As of December 31, 2020, total unrecognized stock compensation expense was $2,538,211, which will be recognized as those options vest over a period of approximately four years. The amount of future stock option compensation expense could be affected by any future option grants or by any option holders leaving the Company before their grants are fully vested. Net Loss Per Share of Common Stock Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. Potentially dilutive securities are excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive and consist of the following: As of December 31, 2020 2019 Options 7,469,891 7,632,358 Warrants 19,372,818 4,907,223 Totals 26,842,709 12,539,581 Recent Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 “ Debt—Debt with Conversion and Other Options Hedging—Contracts in Entity’s Own Equity

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	Note 4 - Property and Equipment Property and equipment consist of the following: As of December 31, 2020 2019 Lab equipment $ 860,433 $ 839,802 Computer and equipment 65,665 60,384 Total property and equipment $ 926,098 $ 900,186 Less: accumulated depreciation (532,094 ) (376,509 ) Total property and equipment, net $ 394,004 $ 523,677 Depreciation expense related to property and equipment for the years ended December 31, 2020 and 2019 was $155,585 and $147,441, respectively. During the year ended December 31, 2019, the Company wrote off fully depreciated assets and adjusted the carrying value of the assets and accumulated depreciation by $833, respectively.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	Note 5 – Intangible Assets Intangible assets consist of the following: As of December 31, 2020 2019 Intangible assets: patents $ 21,604 $ 21,604 Less: amortization (3,529 ) (2,450 ) Total intangible assets, net $ 18,075 $ 19,154 Amortization expense for each of the years ended December 31, 2020 and 2019 was $1,079. The Company will recognize intangible amortization expense of $1,079 in each of the next five years. Thereafter, amortization expense will total $12,680.

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2020
Accrued Liabilities [Abstract]
ACCRUED LIABILITIES	Note 6 – Accrued Liabilities Accrued liabilities consist of the following: As of December 31, 2020 2019 Lab services & supplies $ 917,194 $ 131,176 Professional fees 44,171 61,662 Interest 162,731 544,199 Other 17,645 179,655 Total accrued liabilities $ 1,141,741 $ 916,692

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
NOTES PAYABLE	Note 7 - Notes Payable During the year ended December 31, 2020, the Company completed a private offering (the “Private Offering”) with certain promissory note holders converting outstanding amounts due under its 8% Unsecured Promissory Notes (the “Notes”) due in 2021 and 2022. The Company converted the Notes in the Private Offering totaling an aggregate of $3,847,018 in principal and interest and issued 3,154,115 units at a price of $1.22 per unit. Two officers of the Company participated in the private offering converting an aggregate of approximately $131,000 into 107,000 units. Each unit consists of one share of the Company’s common stock and one warrant to purchase 0.75 of one share of the Company’s common stock at an exercise price of $1.44 per share. Each warrant can be exercised at any time on or after June 18, 2021 and on or prior to June 18, 2026. As of December 31, 2020, the aggregate principal balance of the promissory notes totaling $740,000 remains outstanding. Of such amount, $365,000 in aggregate principal amount is due and payable 2021 and $375,000 in aggregate principal amount is due and payable in 2022.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	Note 8 - Commitments and Contingencies Litigations, Claims and Assessments The Company may from time to time be a party to litigation and subject to claims incident to the ordinary course of business. As the Company grows and gains prominence in the marketplace it may become a party to an increasing number of litigation matters and claims. The outcome of litigation and claims cannot be predicted with certainty, and the resolution of these matters could materially affect the Company’s future results of operations, cash flows or financial position. The Company is not currently a party to any legal proceedings. Licensing Agreements The Company is a party to an Exclusive License Agreement (the “2011 Exclusive Agreement”) with the Regents of the University of California (“the Regents” or “Licensors”) which remains in effect for the life of the last-to-expire patent or last to be abandoned patent application, whichever is later. The Company agreed to pay the Licensors specified development milestone payments aggregating up to $765,000 for the first product sold under the license. Milestone payments for additional products developed and sold under the license are reduced by 50%. The Company is also required to pay annual maintenance fees to the Licensors. Aggregate maintenance fees for the first five years following execution of the agreement were $80,000. Thereafter, the Company is required to pay maintenance fees of $50,000 annually until the first sale of a licensed product. In addition, for the duration of the 2011 Exclusive Agreement, the Company is required to pay the Licensors royalties equal to 2% of its worldwide net sales of drugs, therapies or other products developed from claims covered by the licensed patents, subject to a minimum royalty payment of $75,000 annually, beginning after the first commercial sale of a licensed product. The Company is required to pay royalties ranging from 8% of worldwide sublicense sales of covered products (if the sublicense is entered after commencement of Phase II clinical trials) to 12% of worldwide sublicense sales (if the sublicense is entered prior to commencement of Phase I clinical trials). The agreement also requires the Company to meet certain diligence and development milestones, including filing of an Investigational New Drug (“IND”) Application for a product covered by the agreement on or before the seventh anniversary of the agreement date. In October 2020, the Regents accepted the Company’s payment for an additional year of license maintenance. Through December 31, 2020, no royalties have been incurred under the agreement. All maintenance fees due and payable have been paid. The Company is also a party to an Exclusive License Agreement (the “2013 Exclusive Agreement”) with the Regents whereby the Regents granted to the Company an exclusive license for the use of certain other patents. The 2013 Exclusive Agreement remains in effect for the life of the last-to-expire patent or last to be abandoned patent application, whichever is later. The Company paid the Regents an initial license issue fee of $10,000 for these other patents, which was charged to General and Administrative expense, as incurred. The Company is also required to pay annual maintenance fees to the Licensors. Aggregate maintenance fees for the first three years following execution of the agreement were $7,500. Thereafter, the Company is required to pay maintenance fees of $5,000 annually until the first sale of a licensed product. The Company agreed to pay the Regents specified development milestone payments aggregating up to $765,000 for the first product sold under the 2013 Exclusive Agreement. Milestone payments for additional products developed and sold under the 2013 Exclusive Agreement are reduced by 50%. In addition, for the duration of the 2013 Exclusive Agreement, the Company is required to pay the Regents royalties equal to 2% of the Company’s worldwide net sales of drugs, therapies or other products developed from claims covered by the licensed patent, subject to a minimum royalty payment of $75,000 annually, beginning after the first commercial sale of a licensed product. The Company is required to pay the Regents royalties ranging from 8% of worldwide sublicense sales of covered products (if the sublicense is entered after commencement of Phase II clinical trials) to 12% of worldwide sublicense sales (if the sublicense is entered prior to commencement of Phase I clinical trials). The agreement also requires the Company to meet certain diligence and development milestones, including filing of an IND Application for a product covered by the agreement on or before the seventh anniversary of the agreement date. Through December 31, 2020, no royalties have been incurred under the agreement. All maintenance fees due and payable have been paid. Operating Leases The Company is a party to a lease agreement for laboratory space leased on a month-to-month basis that is part of a shared facility in Menlo Park, California. In September 2020, the Company renewed its lease for office space in Fairfield, New Jersey for an additional year at the same annual cost of $13,080 per annum. Rent expense amounted to $403,449 and $350,979 for the years ended December 31, 2020 and 2019, respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
INCOME TAXES	Note 9 - Income Taxes The tax effects of temporary differences that give rise to deferred tax assets are as follows: As of December 31, 2020 2019 Current: Accrued expenses $ 464,042 $ 223,712 Stock compensation 869,815 838,753 Net operating loss carryforward 16,165,927 11,978,595 Research and development credit carry forward 548,983 367,261 Total deferred tax assets 18,048,767 13,408,321 Valuation allowance (18,048,767 ) (13,408,321 ) Deferred tax asset, net of valuation allowance $ - $ - A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows: For the Years Ended 2020 2019 U.S. statutory federal rate (21.0 )% (21.0 )% State income taxes, net of federal tax (7.0 )% (7.0 )% Federal tax rate change - % - % Permanent differences 0.4 % 3.0 % Prior year true-ups (0.4 )% 0.3 % R&D tax credit (0.5 )% (0.7 )% Change in valuation allowance 28.5 % 25.4 % Income tax provision (benefit) - % - % The income tax provision consists of the following: For the Years Ended 2020 2019 Federal Current $ - $ - Deferred (3,482,375 ) (2,378,218 ) State and local Current - - Deferred (1,158,072 ) (790,882 ) Change in valuation allowance 4,640,447 3,169,100 Income tax provision (benefit) $ - $ - The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not more-likely-than-not, a valuation allowance is established. Based upon the Company’s losses since inception, management believes that it is more-likely-than-not that future benefits of deferred tax assets will not be realized. Therefore, the Company established a full valuation allowance as of December 31, 2020 and 2019. As of December 31, 2020 and 2019, the change in valuation allowance was $4,640,447 and $3,169,100, respectively. The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions, principally California and New Jersey. The Company is subject to examination by the various taxing authorities. The Company’s federal and state income tax returns for tax years beginning in 2015 remain subject to examination. At December 31, 2020 and 2019, the Company had approximately $58,000,000 and $43,000,000, respectively, of federal and state net operating loss carryovers that may be available to offset future taxable income. The Company’s 2017 and prior federal and state net operating loss carry forwards, if not utilized, will begin to expire from 2029 to 2037. Beginning with 2018, and for subsequent years, the Company’s NOLs will have indefinite lives for federal tax purposes. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years. In accordance with Section 382 of the Internal Revenue Code, the usage of the Company’s net operating loss carryforward could be limited in the event of a change in ownership. At this time, the Company has not completed a full study to assess whether an ownership change under Section 382 of the Code occurred due to the costs and complexities associated with such a study. At December 31, 2020 and 2019, the Company had approximately $549,000 and $367,000, respectively, in gross R&D tax credits. These R&D tax credits will begin to expire from 2033 to 2040, respectively.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	Note 10 - Stockholders’ Equity Authorized Capital The Company has authorized the issuance and sale of up to 185,000,000 shares of stock, consisting of 180,000,000 shares of common stock having a par value of $0.001 and 5,000,000 shares of Preferred Stock having a par value of $0.001 per share. As of December 31, 2020 and 2019, there were no shares of Preferred Stock outstanding and there were no declared but unpaid dividends or undeclared dividend arrearages on any shares of the Company’s capital stock. At-the-Market Offering During the year ended December 31, 2020, the Company entered into an At-the-Market Offering Sales Agreement (“ATM”) with Virtu Americas, LLC as sales agent. During the year ended December 31, 2020, the Company sold 2,350,067 shares of its common stock under the ATM program for proceeds of $4,308,352, net of commissions and professional fees of $214,456. Underwritten Public Offering During the year ended December 31, 2020, the Company completed an underwritten public offering of the Company’s securities (the “Public Offering”) pursuant to which the Company sold 12,300,000 shares of its common stock and warrants to purchase 10,608,750 shares of common stock for proceeds of $13,655,531, net of commissions and professional fees of $1,368,919. The warrants issued in the Public Offering were immediately exercisable and have a term of five years and a per share exercise price of $1.44. Stock Options The Company has an incentive stock plan, the Amended and Restated 2011 Equity Incentive Plan (the “2011 Plan”), and has granted stock options to employees, non-employee directors and consultants from the 2011 Plan. Options granted under the 2011 Plan may be Incentive Stock Options or Non-statutory Stock Options, as determined by the Administrator at the time of grant. During the year ended December 31, 2020, the Company’s stockholders approved an amendment to the 2011 Plan to increase the number of shares authorized for issuance under the 2011 Plan to a total of 14,000,000. As of December 31, 2020, there were 5,129,109 shares remaining available for issuance under the 2011 Plan. During the year ended December 31, 2020, the Company granted stock options to employees to purchase 275,000 shares of the Company’s common stock at exercise prices that ranged between $1.55 to $2.56 per share. The options have terms of ten years. The stock options have an aggregate grant date fair value of $486,273. During the year ended December 31, 2020, stock options to purchase 223,924 shares of common stock were exercised for cash proceeds of $252,385. During the year ended December 31, 2020, stock options to purchase 213,543 shares of common stock were cancelled and returned to the option pool for future issuance. During the year ended December 31, 2019, the Company granted stock options to employees to purchase 2,279,000 shares of the Company’s common stock at exercise prices that ranged between $1.43 to $3.15 per share. The options have terms of ten years. The stock options have an aggregate grant date fair value of $3,471,351. During the year ended December 31, 2019, 441,210 stock options were exercised for cash proceeds of $552,110 and the Company cancelled 193,714 stock options. The Company recorded stock-based compensation as follows: For the Years Ended 2020 2019 Research and development $ 604,107 $ 915,075 General and administrative 1,612,209 1,694,295 Total $ 2,216,316 $ 2,609,370 The following table represents stock option activity for the years ended December 31, 2020 and 2019: Weighted Average Stock Options Exercise Price Fair Value Contractual Aggregate Outstanding Exercisable Outstanding Exercisable Vested Life (Years) Intrinsic Value Balance – January 1, 2019 5,488,282 4,384,294 $ 2.10 $ 1.32 $ 1.32 5.80 $ - Granted 2,779,000 - - - - - - Exercised (441,210 ) - - - - - - Cancelled (193,714 ) - - - - - - Balance – December 31, 2019 7,632,358 4,542,144 $ 2.21 $ 1.57 $ 1.57 6.44 $ - Granted 275,000 - - - - - - Exercised (223,924 ) - - - - - - Cancelled (213,543 ) - - - - - - Balance – December 31, 2020 7,469,891 5,390,431 $ 2.06 $ 1.68 $ 1.68 6.27 $ 1,634,719 The following table summarizes information on stock options outstanding and exercisable as of December 31, 2020: Grant Price Weighted Average Total Number Weighted Average From To Exercise Price Outstanding Exercisable Contractual Term $ 0.26 $ 2.02 $ 0.89 3,119,974 2,935,807 3.48 years $ 2.10 $ 4.60 $ 2.42 3,756,917 1,914,915 7.76 years $ 5.30 $ 8.86 $ 6.25 593,000 539,709 7.34 years Totals 7,469,891 5,390,431 Warrants During the year ended December 31, 2020, the Company issued warrants to purchase 10,608,750 shares of the Company’s common stock as part of the Public Offering (see Note 8 – Underwritten Public Offering) and to the note holders that extended the due date of their unsecured promissory notes (see Note 10 – Amendments to Notes and Warrants) and warrants to purchase 2,365,595 shares of the Company’s common stock as part of the Private Offering that converted outstanding amounts due under the Company’s 8% Unsecured Promissory Notes due 2021 (see Note 7 - Notes Payable). During the year ended December 31, 2020, the Company entered into amendments (the “Amendments”) with certain holders of the Company’s 8% Unsecured Promissory Notes (the “2018 Notes”) and Nontransferable Common Stock Purchase Warrants (the “2018 Warrants”). Pursuant to the Amendments, the maturity date of the applicable 2018 Notes was extended from March 29, 2021 to June 30, 2021 and the expiration date of the applicable 2018 Warrants was extended from March 29, 2021 to March 29, 2022. The terms of the applicable 2018 Notes were also amended to grant the holders of such 2018 Notes a right to participate in a future private offering of the Company’s securities upon terms substantially similar to those offered to investors in a future primary offering of the Company’s securities and to grant resale registration rights in connection therewith. The Company recognized $209,810 of non-cash costs in Other Expenses in the accompanying statements of operations relating to the 2018 Warrants extension. The Company subsequently entered into a second amendment to the 2018 Notes with certain holders whereby the maturity date of the applicable 2018 Notes was extended from June 30, 2021 to June 30, 2022 and the expiration date of the applicable 2018 Warrants was extended from March 29, 2022 to March 29, 2026. The exercise price of the 2018 Warrants was adjusted from $5.30 per share to $2.00 per share. The terms of the applicable 2018 Notes were also amended to require that the holders of such 2018 Notes participate in a future private offering of the Company’s securities upon terms substantially similar to those offered to investors in a future primary offering of the Company’s securities (see Note 7 – Notes Payable). The Company also granted an additional warrant to purchase 0.5 of one share of its common stock, or 1,511,250 shares of common stock in total, per dollar of each participating 2018 Note holder’s principal amount of the 2018 Notes with an exercise price of $2.00 per share and an expiration date of March 29, 2026 (the “New Warrants”). The New Warrants will be exercisable beginning on the six-month anniversary of the date of issuance, and the Company granted to the participating 2018 Note holders certain registration rights with respect to its securities issued in the Private Offering and the shares of common stock underlying the New Warrants. The Company recognized $489,645 of non-cash costs in Other Expenses in the accompanying statements of operations related to this second amendment. Also, during the year ended December 31, 2020, the Company entered into amendments with certain holders of the Company’s Common Stock Purchase Warrants (the “2017 Warrants”) pursuant to which the expiration date of the applicable 2017 Warrants was extended from June 30, 2020 to September 30, 2021. The Company recognized $1,591,233 of non-cash costs in Other Expenses in the accompanying statements of operations relating to the 2017 Warrants extension. The Company determined the proper classification of the loan modification based on ASC 470-50, Debt Modifications and Extinguishments. Because the change in present value of cash flows of the modified debt is less than 10% when compared to the present value of the cash flows of the original debt, no change is required to be made to the debt in the accompanying condensed financial statements. During the year ended December 31, 2020, warrants to purchase 20,000 shares of common stock were exercised for cash proceeds of $45,000. During the year ended December 31, 2019, warrants to purchase 50,000 shares of the Company’s common stock were exercised for cash proceeds of $57,500. During the year ended December 31, 2019, warrants to purchase 6,982 shares of the Company’s common stock expired and were cancelled. The following table represents warrant activity for the years ended December 31, 2020 and 2019: Weighted Average Warrants Exercise Price Fair Value Contractual Aggregate Outstanding Exercisable Outstanding Exercisable Vested Life (Years) Intrinsic Value Balance – January 1, 2019 4,964,205 4,964,205 $ 2.39 $ 2.39 $ 1.14 2.27 $ - Granted - - - - - - - Exercised (50,000 ) - - - - - - Cancelled (6,982 ) - - - - - - Balance – December 31, 2019 4,907,223 4,907,223 $ 2.40 $ 2.40 $ 1.11 1.55 $ 833,793 Granted 14,485,595 - - - - - - Exercised (20,000 ) - - - - - - Cancelled - - - - - - - Balance – December 31, 2020 19,372,818 15,495,973 $ 1.62 $ 1.61 $ 0.81 4.07 $ 866,300

Non-Cash Expenses

Non-Cash Expenses	12 Months Ended
	Dec. 31, 2020
Other Income and Expenses [Abstract]
NON-CASH EXPENSES	Note 11 – Non-Cash Expenses The following table details the Company’s non-cash expenses included in the accompanying statements of operations: For the Years Ended 2020 2019 Operating expenses: Stock-based compensation $ 2,216,316 $ 2,609,370 Depreciation & amortization 156,664 148,520 Subtotal $ 2,372,980 $ 2,757,890 Other expense: Amortization of debt discount 504,498 420,341 Equity modification 2,290,688 - Subtotal $ 2,795,186 $ 420,341 Total non-cash expenses $ 5,168,166 $ 3,178,231

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	Note 12 - Subsequent Events Management has evaluated subsequent events to determine if events or transactions occurring through the date on which the financial statements were issued require adjustment or disclosure in the Company’s financial statements. Subsequent to December 31, 2020, a total of 623,901 stock options were exercised for cash proceeds of $958,847. Subsequent to December 31, 2020, a total of 46,900 warrants were exercised for cash proceeds of $67,536. Subsequent to December 31, 2020, the Company granted warrants to purchase a total of 60,000 shares of the Company’s common stock with an exercise price of $1.38 per share. The warrants have terms that range from two to three years with vesting over a one-year period. Subsequent to December 31, 2020, the company repaid two promissory notes totaling approximately $105,000 in principal and interest.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
BASIS OF PRESENTATION	Basis of Presentation All amounts are presented in U.S. Dollars.
USE OF ESTIMATES	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at dates of the financial statements and the reported amounts of revenue and expenses during the periods. Actual results could differ from these estimates. The Company’s significant estimates and assumptions include the fair value of financial instruments, stock-based compensation and the valuation allowance relating to the Company’s deferred tax assets.
CONCENTRATIONS OF CREDIT RISK	Concentrations of Credit Risk The Company maintains deposits in a financial institution which is insured by the Federal Deposit Insurance Corporation (“FDIC”). At various times, the Company has deposits in this financial institution in excess of the amount insured by the FDIC. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.
INVESTMENTS	Investments Investments as of December 2020 and 2019 consist of U.S. Treasury Bills, which are classified as held-to-maturity, and Certificates of Deposit totaling $18,120,266 and $0, respectively. The Company determines the appropriate balance sheet classification of its investments at the time of purchase and evaluates the classification at each balance sheet date. All of the Company’s U.S. Treasury Bills mature within the subsequent twelve months from the date of purchase. Unrealized gains and losses were de minimus
CAPITALIZATION OF PATENT COSTS	Capitalization of Patent Costs The Company capitalizes the costs of its patents which consists of legal and filing fees related to the prosecution of patent filings. The patents will be amortized using the straight-line method over the estimated remaining lives of the patents which is 20 years from the initial filing of the patent.
CASH EQUIVALENTS	Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of December 31, 2020, the Company did not have any cash equivalents. As of December 31, 2019, the Company invested $9,505,777 in Treasury Bills that are considered cash equivalents due to their maturity date being less than three months from the date of purchase.
PROPERTY AND EQUIPMENT, NET	Property and Equipment, net Property and equipment are stated at cost less accumulated depreciation. Depreciation of computer and lab equipment is computed by use of the straight-line method based on the estimated useful lives of the assets, which range from three to five years. Expenditures for maintenance and repairs that do not improve or extend the expected lives of the assets are expensed to operations, while expenditures for major upgrades to existing items are capitalized. Upon retirement or other disposition of these assets, the costs and accumulated depreciation are removed from the accounts and resulting gains or losses are reflected in the results of operations.
FAIR VALUE OF FINANCIAL INSTRUMENTS	Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company utilizes three levels of inputs that may be used to measure fair value: Level 1 - quoted prices in active markets for identical assets or liabilities Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions) The carrying amounts of cash, investments and accounts payable approximate fair value due to the short-term nature of these instruments. The amount of debt included in the accompanying balance sheets approximates its fair value because the interest rate of the notes approximates the current market interest rate.
COMMON STOCK PURCHASE WARRANTS	Common Stock Purchase Warrants The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provides the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company’s own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control), or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets, liabilities and equity is required. The Company’s free-standing derivatives consist of warrants to purchase common stock that were issued in connection with its notes payable and private offering. The Company evaluated these warrants to assess their proper classification using the applicable criteria enumerated under U.S. GAAP and determined that the common stock purchase warrants meet the criteria for equity classification in the accompanying balance sheets as of December 31, 2020 and 2019.
INCOME TAXES	Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The benefit of tax positions taken or expected to be taken in income tax returns are recognized in the financial statements if such positions are more likely than not of being sustained. Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s financial statements as of December 31, 2020 and 2019. The Company does not expect any significant changes in the unrecognized tax benefits within twelve months of the reporting date. The Company classifies interest expense and any related penalties related to income tax uncertainties as a component of income tax expense. No interest or penalties have been recognized during the years ended December 31, 2020 and 2019.
RESEARCH AND DEVELOPMENT EXPENSES	Research and Development Expenses The Company expenses all research and development expenses as incurred. These costs include payroll, employee benefits, supplies, contracted for lab services, depreciation and other personnel-related costs associated with product development.
Share-Based Payment	Share-Based Payment The Company accounts for share-based payments using the fair value method. For employees and directors, the fair value of the award is measured, as discussed below, on the grant date. For non-employees, fair value is generally valued based on the fair value of the services provided or the fair value of the equity instruments on the measurement date, whichever is more readily determinable. The Company has granted stock options at exercise prices equal to the closing price of the Company’s common stock as reported by Nasdaq, with input from management on the date of grant. Upon exercise of an option or warrant, the Company issues new shares of common stock out of its authorized shares. The weighted-average fair value of options and warrants has been estimated on the grant date or measurement date using the Black-Scholes pricing model. The fair value of each instrument is estimated on the grant date or measurement date utilizing certain assumptions for a risk-free interest rate, volatility and expected remaining lives of the awards. The risk-free interest rate used is the United States Treasury rate for the day of the grant having a term equal to the life of the equity instrument. Beginning with the first quarter of the year ending 2019, the fair value of stock-based payment awards issued was estimated using a volatility derived from the Company’s share price. Prior to the first quarter of the year ending 2019, the Company had a limited history of being publicly traded and estimated the fair value of stock-based payment awards using a volatility derived from an index of comparable entities. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company’s stock-based compensation expense could be materially different in the future. The weighted-average Black-Scholes assumptions are as follows: For the Years Ended 2020 2019 Expected life 6 years 6 years Risk free interest rate 0.85 % 2.18 % Expected volatility 97 % 77 % Expected dividend yield 0 % 0 % As of December 31, 2020, total unrecognized stock compensation expense was $2,538,211, which will be recognized as those options vest over a period of approximately four years. The amount of future stock option compensation expense could be affected by any future option grants or by any option holders leaving the Company before their grants are fully vested.
NET LOSS PER SHARE OF COMMON STOCK	Net Loss Per Share of Common Stock Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. Potentially dilutive securities are excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive and consist of the following: As of December 31, 2020 2019 Options 7,469,891 7,632,358 Warrants 19,372,818 4,907,223 Totals 26,842,709 12,539,581
RECENT ACCOUNTING PRONOUNCEMENTS	Recent Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 “ Debt—Debt with Conversion and Other Options Hedging—Contracts in Entity’s Own Equity

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Schedule of weighted-average Black-Scholes assumptions	For the Years Ended 2020 2019 Expected life 6 years 6 years Risk free interest rate 0.85 % 2.18 % Expected volatility 97 % 77 % Expected dividend yield 0 % 0 %
Schedule of anti-dilutive securities excluded from computation of diluted net loss per share	As of December 31, 2020 2019 Options 7,469,891 7,632,358 Warrants 19,372,818 4,907,223 Totals 26,842,709 12,539,581

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	As of December 31, 2020 2019 Lab equipment $ 860,433 $ 839,802 Computer and equipment 65,665 60,384 Total property and equipment $ 926,098 $ 900,186 Less: accumulated depreciation (532,094 ) (376,509 ) Total property and equipment, net $ 394,004 $ 523,677

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible assets	As of December 31, 2020 2019 Intangible assets: patents $ 21,604 $ 21,604 Less: amortization (3,529 ) (2,450 ) Total intangible assets, net $ 18,075 $ 19,154

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2020
Accrued Liabilities [Abstract]
Schedule of accrued liabilities	As of December 31, 2020 2019 Lab services & supplies $ 917,194 $ 131,176 Professional fees 44,171 61,662 Interest 162,731 544,199 Other 17,645 179,655 Total accrued liabilities $ 1,141,741 $ 916,692

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of deferred tax assets	As of December 31, 2020 2019 Current: Accrued expenses $ 464,042 $ 223,712 Stock compensation 869,815 838,753 Net operating loss carryforward 16,165,927 11,978,595 Research and development credit carry forward 548,983 367,261 Total deferred tax assets 18,048,767 13,408,321 Valuation allowance (18,048,767 ) (13,408,321 ) Deferred tax asset, net of valuation allowance $ - $ -
Schedule of statutory federal income tax rate	For the Years Ended 2020 2019 U.S. statutory federal rate (21.0 )% (21.0 )% State income taxes, net of federal tax (7.0 )% (7.0 )% Federal tax rate change - % - % Permanent differences 0.4 % 3.0 % Prior year true-ups (0.4 )% 0.3 % R&D tax credit (0.5 )% (0.7 )% Change in valuation allowance 28.5 % 25.4 % Income tax provision (benefit) - % - %
Schedule of income tax provision	For the Years Ended 2020 2019 Federal Current $ - $ - Deferred (3,482,375 ) (2,378,218 ) State and local Current - - Deferred (1,158,072 ) (790,882 ) Change in valuation allowance 4,640,447 3,169,100 Income tax provision (benefit) $ - $ -

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
Schedule of stock-based compensation	For the Years Ended 2020 2019 Research and development $ 604,107 $ 915,075 General and administrative 1,612,209 1,694,295 Total $ 2,216,316 $ 2,609,370
Schedule of stock option activity	Weighted Average Stock Options Exercise Price Fair Value Contractual Aggregate Outstanding Exercisable Outstanding Exercisable Vested Life (Years) Intrinsic Value Balance – January 1, 2019 5,488,282 4,384,294 $ 2.10 $ 1.32 $ 1.32 5.80 $ - Granted 2,779,000 - - - - - - Exercised (441,210 ) - - - - - - Cancelled (193,714 ) - - - - - - Balance – December 31, 2019 7,632,358 4,542,144 $ 2.21 $ 1.57 $ 1.57 6.44 $ - Granted 275,000 - - - - - - Exercised (223,924 ) - - - - - - Cancelled (213,543 ) - - - - - - Balance – December 31, 2020 7,469,891 5,390,431 $ 2.06 $ 1.68 $ 1.68 6.27 $ 1,634,719
Schedule of stock options outstanding and exercisable	Grant Price Weighted Average Total Number Weighted Average From To Exercise Price Outstanding Exercisable Contractual Term $ 0.26 $ 2.02 $ 0.89 3,119,974 2,935,807 3.48 years $ 2.10 $ 4.60 $ 2.42 3,756,917 1,914,915 7.76 years $ 5.30 $ 8.86 $ 6.25 593,000 539,709 7.34 years Totals 7,469,891 5,390,431
Schedule of warrants activity	Weighted Average Warrants Exercise Price Fair Value Contractual Aggregate Outstanding Exercisable Outstanding Exercisable Vested Life (Years) Intrinsic Value Balance – January 1, 2019 4,964,205 4,964,205 $ 2.39 $ 2.39 $ 1.14 2.27 $ - Granted - - - - - - - Exercised (50,000 ) - - - - - - Cancelled (6,982 ) - - - - - - Balance – December 31, 2019 4,907,223 4,907,223 $ 2.40 $ 2.40 $ 1.11 1.55 $ 833,793 Granted 14,485,595 - - - - - - Exercised (20,000 ) - - - - - - Cancelled - - - - - - - Balance – December 31, 2020 19,372,818 15,495,973 $ 1.62 $ 1.61 $ 0.81 4.07 $ 866,300

Non-Cash Expenses (Tables)

Non-Cash Expenses (Tables)	12 Months Ended
	Dec. 31, 2020
Other Income and Expenses [Abstract]
Schedule of non-cash expenses	For the Years Ended 2020 2019 Operating expenses: Stock-based compensation $ 2,216,316 $ 2,609,370 Depreciation & amortization 156,664 148,520 Subtotal $ 2,372,980 $ 2,757,890 Other expense: Amortization of debt discount 504,498 420,341 Equity modification 2,290,688 - Subtotal $ 2,795,186 $ 420,341 Total non-cash expenses $ 5,168,166 $ 3,178,231

Liquidity and Management's Pl_2

Liquidity and Management's Plans (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Managements Liquidity Plans Disclosure [Abstract]
Cash and cash equivalents	$ 2,894,575	$ 12,563,853	$ 5,722,342
Working capital	18,356,514
Stockholders' equity	18,487,155	8,136,826	$ 17,962,618
Net loss	(16,264,961)	$ (13,044,772)
Funding from equity exercises	$ 1,000,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Certificates of deposit	$ 18,120,266	$ 0
Estimated useful lives of the assets	20 years
Treasury bills that are considered cash equivalents		$ 9,505,777
Unrecognized stock option compensation expense	$ 2,538,211
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodTerm	approximately four years.

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of weighted-average Black-Scholes assumptions - Equity Option [Member]	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Summary of Significant Accounting Policies (Details) - Schedule of weighted-average Black-Scholes assumptions [Line Items]
Expected life	6 years	6 years
Risk free interest rate	0.85%	2.18%
Expected volatility	97.00%	77.00%
Expected dividend yield	0.00%	0.00%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive securities excluded from computation of diluted net loss per share - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share, Amount	26,842,709	12,539,581
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share, Amount	19,372,818	4,907,223
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share, Amount	7,469,891	7,632,358

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation expenses	$ 155,585	$ 147,441
Adjusted the carrying value of the assets and accumulated depreciation	$ 833

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of property and equipment - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 926,098	$ 900,186
Less: accumulated depreciation	(532,094)	(376,509)
Total property and equipment, net	394,004	523,677
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	860,433	839,802
Computer and equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 65,665	$ 60,384

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization	$ 1,079	$ 1,079
Finite-Lived Intangible Asset, Expected Amortization, after Year Five	1,079
Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five	$ 12,680

Intangible Assets (Details) - S

Intangible Assets (Details) - Schedule of Intangible assets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Schedule of Intangible assets [Abstract]
Intangible assets: patents	$ 21,604	$ 21,604
Less: amortization	(3,529)	(2,450)
Total intangible assets, net	$ 18,075	$ 19,154

Accrued Liabilities (Details) -

Accrued Liabilities (Details) - Schedule of accrued liabilities - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Schedule of accrued liabilities [Abstract]
Lab services & supplies	$ 917,194	$ 131,176
Professional fees	44,171	61,662
Interest	162,731	544,199
Other	17,645	179,655
Total accrued liabilities	$ 1,141,741	$ 916,692

Notes Payable (Details)

Notes Payable (Details)	12 Months Ended
	Dec. 31, 2020USD ($)$ / sharesshares
Notes Payable (Details) [Line Items]
Rate of interest on unsecured promissory notes	8.00%
Aggregate principal amount	$ 3,847,018
Share issued | shares	3,154,115
Share price | $ / shares	$ 1.22
Convertion of private offering price	$ 3,847,018
Warrant description	Each unit consists of one share of the Company’s common stock and one warrant to purchase 0.75 of one share of the Company’s common stock at an exercise price of $1.44 per share. Each warrant can be exercised at any time on or after June 18, 2021 and on or prior to June 18, 2026. As of December 31, 2020, the aggregate principal balance of the promissory notes totaling $740,000 remains outstanding. Of such amount, $365,000 in aggregate principal amount is due and payable 2021 and $375,000 in aggregate principal amount is due and payable in 2022.
Two Officers [Member]
Notes Payable (Details) [Line Items]
Convertion of private offering price	$ 131,000
Share of convertion private offering price | shares	107,000

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Commitments and Contingencies (Details) [Line Items]
Rent expense for space	$ 13,080
Rent expense		$ 403,449	$ 350,979
2011 Exclusive Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Milestone payment		$ 765,000
License reduced percentage		50.00%
Aggregate maintenance fees		$ 80,000
Maintenance fees annually		$ 50,000
Royalty percentage		2.00%
Minimum royalty expense		$ 75,000
Royalty description		The Company is required to pay royalties ranging from 8% of worldwide sublicense sales of covered products (if the sublicense is entered after commencement of Phase II clinical trials) to 12% of worldwide sublicense sales (if the sublicense is entered prior to commencement of Phase I clinical trials).
2013 Exclusive Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Milestone payment		$ 765,000
License reduced percentage		50.00%
Aggregate maintenance fees		$ 7,500
Maintenance fees annually		$ 5,000
Royalty percentage		2.00%
Minimum royalty expense		$ 75,000
License costs		$ 10,000
Royalty description		The Company is required to pay the Regents royalties ranging from 8% of worldwide sublicense sales of covered products (if the sublicense is entered after commencement of Phase II clinical trials) to 12% of worldwide sublicense sales (if the sublicense is entered prior to commencement of Phase I clinical trials).

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Change in valuation allowance	$ 4,640,447	$ 3,169,100
Net operating loss carryovers	$ 58,000,000	43,000,000
Operating loss carry forwards, description	The Company’s 2017 and prior federal and state net operating loss carry forwards, if not utilized, will begin to expire from 2029 to 2037. Beginning with 2018, and for subsequent years, the Company’s NOLs will have indefinite lives for federal tax purposes.
Research and development tax credits	$ 549,000	$ 367,000
Tax credits expire date description	These R&D tax credits will begin to expire from 2033 to 2040, respectively.

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of deferred tax assets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current:
Accrued expenses	$ 464,042	$ 223,712
Stock compensation	869,815	838,753
Net operating loss carryforward	16,165,927	11,978,595
Research and development credit carry forward	548,983	367,261
Total deferred tax assets	18,048,767	13,408,321
Valuation allowance	(18,048,767)	(13,408,321)
Deferred tax asset, net of valuation allowance

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of statutory federal income tax rate	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Schedule of statutory federal income tax rate [Abstract]
U.S. statutory federal rate	(21.00%)	(21.00%)
State income taxes, net of federal tax	(7.00%)	(7.00%)
Federal tax rate change
Permanent differences	0.40%	3.00%
Prior year true-ups	(0.40%)	0.30%
R&D tax credit	(0.50%)	(0.70%)
Change in valuation allowance	28.50%	25.40%
Income tax provision (benefit)

Income Taxes (Details) - Sche_3

Income Taxes (Details) - Schedule of income tax provision - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Federal
Current
Deferred	(3,482,375)	(2,378,218)
State and local
Current
Deferred	(1,158,072)	(790,882)
Change in valuation allowance	4,640,447	3,169,100
Income tax provision (benefit)

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Stockholders' Equity (Details) [Line Items]
Authorized to Issue and sale of stock	185,000,000
Common stock, shares authorized	180,000,000
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock issued under the controlled equity offering program	2,350,067
Controlled equity offering program for proceeds (in Dollars)	$ 4,308,352
Commissions and professional fees (in Dollars)	214,456
Cash proceeds of exercised, stock options (in Dollars)	$ 252,385	$ 552,110
Percentage of unsecured promissory note	8.00%
Non cash expenses (in Dollars)	$ 209,810
Proceeds from exercise of warrants (in Dollars)	$ 45,000	$ 57,500
Equity Option [Member]
Stockholders' Equity (Details) [Line Items]
Options exercised	223,924	441,210
Number of options cancelled	213,543	193,714
2017 Warrants [Member]
Stockholders' Equity (Details) [Line Items]
Non cash expenses (in Dollars)	$ 1,591,233
Equity Option [Member]
Stockholders' Equity (Details) [Line Items]
Cash proceeds of exercised, stock options (in Dollars)	$ 252,385	$ 552,110
Number of options cancelled	213,543
Share-based Payment Arrangement, Option [Member]
Stockholders' Equity (Details) [Line Items]
Stock options granted to employees	275,000
Recognized options and warrants vest over period	10 years
Stock option aggregate grant fair value (in Dollars)	$ 486,273
Share-based Payment Arrangement, Option [Member] | Minimum [Member]
Stockholders' Equity (Details) [Line Items]
Common stock, per share (in Dollars per share)	$ 1.55
Share-based Payment Arrangement, Option [Member] | Maximum [Member]
Stockholders' Equity (Details) [Line Items]
Common stock, per share (in Dollars per share)	$ 2.56
Employee Stock Option [Member]
Stockholders' Equity (Details) [Line Items]
Stock options granted to employees		2,279,000
Recognized options and warrants vest over period		10 years
Stock option aggregate grant fair value (in Dollars)		$ 3,471,351
Employee Stock Option [Member] | Minimum [Member]
Stockholders' Equity (Details) [Line Items]
Common stock, per share (in Dollars per share)		$ 1.43
Employee Stock Option [Member] | Maximum [Member]
Stockholders' Equity (Details) [Line Items]
Common stock, per share (in Dollars per share)		$ 3.15
Warrant [Member]
Stockholders' Equity (Details) [Line Items]
Warrants issued to purchase common stock	10,608,750
Percentage of unsecured promissory note	8.00%
Warrants, description	The Company also granted an additional warrant to purchase 0.5 of one share of its common stock, or 1,511,250 shares of common stock in total, per dollar of each participating 2018 Note holder’s principal amount of the 2018 Notes with an exercise price of $2.00 per share and an expiration date of March 29, 2026 (the “New Warrants”).
Warrants to purchase common stock exercised	20,000
Cash proceeds from warrants (in Dollars)		$ 50,000
Number of warrants exercised		6,982
Warrant [Member] | Minimum [Member]
Stockholders' Equity (Details) [Line Items]
Price per warrant (in Dollars per share)	$ 2
Warrant [Member] | Maximum [Member]
Stockholders' Equity (Details) [Line Items]
Price per warrant (in Dollars per share)	$ 5.30
2011 Plan [Member]
Stockholders' Equity (Details) [Line Items]
Total number of shares authorized for issuance	14,000,000
Remaining options to be issued	5,129,109
Second amendment [Member] | Warrant [Member]
Stockholders' Equity (Details) [Line Items]
Non cash expenses (in Dollars)	$ 489,645
IPO [Member]
Stockholders' Equity (Details) [Line Items]
Commissions and professional fees (in Dollars)	$ 1,368,919
Sale of common stock	12,300,000
Warrants issued to purchase common stock	10,608,750
Proceeds common stock (in Dollars)	$ 13,655,531
Exercise price (in Dollars per share)	$ 1.44
Private Offering [Member] | Warrant [Member]
Stockholders' Equity (Details) [Line Items]
Warrants issued to purchase common stock	2,365,595

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Schedule of stock-based compensation - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Stockholders' Equity (Details) - Schedule of stock-based compensation [Line Items]
Total	$ 2,216,316	$ 2,609,370
Research and development [Member]
Stockholders' Equity (Details) - Schedule of stock-based compensation [Line Items]
Total	604,107	915,075
General and administrative [Member]
Stockholders' Equity (Details) - Schedule of stock-based compensation [Line Items]
Total	$ 1,612,209	$ 1,694,295

Stockholders' Equity (Details_2

Stockholders' Equity (Details) - Schedule of stock option activity - Equity Option [Member] - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Stockholders' Equity (Details) - Schedule of stock option activity [Line Items]
Stock Options, Outstanding, Beginning Balance (in Shares)	7,632,358	5,488,282
Stock Options, Exercisable, Beginning Balance (in Shares)	4,542,144	4,384,294
Weighted Average, Exercise Price, Outstanding, Beginning Balance	$ 2.21	$ 2.10
Weighted Average, Exercise Price, Exercisable, Beginning Balance	1.57	1.32
Weighted Average, Fair Value Vested, Beginning Balance	$ 1.57	$ 1.32
Weighted Average, Contractual Life (Years), Beginning Balance		5 years 292 days
Aggregate Intrinsic Value, Beginning Balance (in Dollars)
Stock Options, Outstanding, Granted (in Shares)	275,000	2,779,000
Stock Options, Exercisable, Granted (in Shares)
Weighted Average, Exercise Price, Outstanding, Granted
Weighted Average, Exercise Price, Exercisable, Granted
Weighted Average, Fair Value Vested, Granted
Weighted Average, Contractual Life (Years), Granted
Aggregate Intrinsic Value, Granted (in Dollars)
Stock Options, Outstanding, Exercised (in Shares)	(223,924)	(441,210)
Stock Options, Exercisable, Exercised (in Shares)
Weighted Average, Exercise Price, Outstanding, Exercised
Weighted Average, Exercise Price, Exercisable, Exercised
Weighted Average, Fair Value Vested, Exercised
Weighted Average, Contractual Life (Years), Exercised
Aggregate Intrinsic Value, Exercised (in Dollars)
Stock Options, Outstanding, Cancelled (in Shares)	(213,543)	(193,714)
Stock Options, Exercisable, Cancelled (in Shares)
Weighted Average, Exercise Price, Outstanding, Cancelled
Weighted Average, Exercise Price, Exercisable, Cancelled
Weighted Average, Fair Value Vested, Cancelled
Weighted Average, Contractual Life (Years), Cancelled
Aggregate Intrinsic Value, Cancelled (in Dollars)
Stock Options, Outstanding, Ending Balance (in Shares)	7,469,891	7,632,358
Stock Options, Exercisable, Ending Balance (in Shares)	5,390,431	4,542,144
Weighted Average, Exercise Price, Outstanding, Ending Balance	$ 2.06	$ 2.21
Weighted Average, Exercise Price, Exercisable, Ending Balance	1.68	1.57
Weighted Average, Fair Value Vested, Ending Balance	$ 1.68	$ 1.57
Weighted Average, Contractual Life (Years), Ending Balance	6 years 98 days	6 years 160 days
Aggregate Intrinsic Value, Ending Balance (in Dollars)	$ 1,634,719

Stockholders' Equity (Details_3

Stockholders' Equity (Details) - Schedule of stock options outstanding and exercisable	12 Months Ended
	Dec. 31, 2020$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock Options, Weighted Average Exercise Price
Stock Options, Total Outstanding (in Shares) | shares	7,469,891
Stock Options, Number Exercisable (in Shares) | shares	5,390,431
Grant Price From 0.26 To 2.02 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock Options, Grant Price, Minimum	$ 0.26
Stock Options, Grant Price, Maximum	2.02
Stock Options, Weighted Average Exercise Price	$ 0.89
Stock Options, Total Outstanding (in Shares) | shares	3,119,974
Stock Options, Number Exercisable (in Shares) | shares	2,935,807
Stock Options, Weighted Average Remaining Contractual Term	3 years 175 days
Grant Price From 2.10 To 4.60 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock Options, Grant Price, Minimum	$ 2.10
Stock Options, Grant Price, Maximum	4.60
Stock Options, Weighted Average Exercise Price	$ 2.42
Stock Options, Total Outstanding (in Shares) | shares	3,756,917
Stock Options, Number Exercisable (in Shares) | shares	1,914,915
Stock Options, Weighted Average Remaining Contractual Term	7 years 277 days
Grant Price From 5.30 To 8.86 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock Options, Grant Price, Minimum	$ 5.30
Stock Options, Grant Price, Maximum	8.86
Stock Options, Weighted Average Exercise Price	$ 6.25
Stock Options, Total Outstanding (in Shares) | shares	593,000
Stock Options, Number Exercisable (in Shares) | shares	539,709
Stock Options, Weighted Average Remaining Contractual Term	7 years 124 days

Stockholders' Equity (Details_4

Stockholders' Equity (Details) - Schedule of warrants activity - Warrant [Member] - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Class of Warrant or Right [Line Items]
Warrants, Outstanding, Beginning Balance (in Shares)	4,907,223	4,964,205
Warrants, Exercisable, Beginning Balance (in Shares)	4,907,223	4,964,205
Weighted Average, Exercise Price, Outstanding, Beginning Balance	$ 2.40	$ 2.39
Weighted Average, Exercise Price, Exercisable, Beginning Balance	2.40	2.39
Weighted Average, Fair Value Vested, Beginning Balance	$ 1.11	$ 1.14
Weighted Average, Contractual Life (Years), Beginning Balance		2 years 98 days
Aggregate Intrinsic Value, Beginning Balance (in Dollars)	$ 833,793
Warrants, Outstanding, Granted (in Shares)	14,485,595
Warrants, Exercisable, Granted (in Shares)
Weighted Average, Exercise Price, Outstanding, Granted
Weighted Average, Exercise Price, Exercisable, Granted
Weighted Average, Fair Value Vested, Granted
Weighted Average, Contractual Life (Years), Granted
Aggregate Intrinsic Value, Granted (in Dollars)
Warrants, Outstanding, Exercised (in Shares)	(20,000)	(50,000)
Warrants, Exercisable, Exercised (in Shares)
Weighted Average, Exercise Price, Outstanding, Exercised
Weighted Average, Exercise Price, Exercisable, Exercised
Weighted Average, Fair Value Vested, Exercised
Weighted Average, Contractual Life (Years), Exercised
Exercised (in Dollars)
Warrants, Outstanding, Cancelled (in Shares)		(6,982)
Warrants, Exercisable, Cancelled (in Shares)
Weighted Average, Exercise Price, Outstanding, Cancelled
Weighted Average, Exercise Price, Exercisable, Cancelled
Weighted Average, Fair Value Vested, Cancelled
Weighted Average, Contractual Life (Years), Cancelled
Aggregate Intrinsic Value, Cancelled (in Dollars)
Warrants, Outstanding, Ending Balance (in Shares)	19,372,818	4,907,223
Warrants, Exercisable, Ending Balance (in Shares)	15,495,973	4,907,223
Weighted Average, Exercise Price, Outstanding,Ending Balance	$ 1.62	$ 2.40
Weighted Average, Exercise Price, Exercisable, Ending Balance	1.61	2.40
Weighted Average, Fair Value Vested, Ending Balance	$ 0.81	$ 1.11
Weighted Average, Contractual Life (Years), Ending Balance	4 years 25 days	1 year 200 days
Aggregate Intrinsic Value, Ending Balance (in Dollars)	$ 866,300	$ 833,793

Non-Cash Expenses (Details) - S

Non-Cash Expenses (Details) - Schedule of non-cash expenses - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating expenses:
Stock-based compensation	$ 2,216,316	$ 2,609,370
Depreciation & amortization	156,664	148,520
Subtotal	2,372,980	2,757,890
Other expense:
Amortization of debt discount	504,498	420,341
Equity Modification	2,290,688
Subtotal	2,795,186	420,341
Total non-cash expenses	$ 5,168,166	$ 3,178,231

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Subsequent Events (Details) [Line Items]
Cash proceeds	$ 252,385	$ 552,110
Stock Option [Member]
Subsequent Events (Details) [Line Items]
Option exercised (in Shares)	623,901
Cash proceeds	$ 958,847
Warrant [Member]
Subsequent Events (Details) [Line Items]
Warrants exercised (in Shares)	46,900
Cash proceeds from warrants	$ 67,536
Warrants, description	the Company granted warrants to purchase a total of 60,000 shares of the Company’s common stock with an exercise price of $1.38 per share. The warrants have terms that range from two to three years with vesting over a one-year period.
Two Promissory Notes [Member]
Subsequent Events (Details) [Line Items]
Aggregate of principle and interest	$ 105,000